Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study

So, Alexander; De Meulemeester, Marc; Pikhlak, A.; Yücel, Eftal; Richard, Dominik; Murphy, V.; Arulmani, Udayasankar; Sallstig, Peter; Schlesinger, Naomi

doi:10.1002/art.27600

Public

Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study

Published in Arthritis & Rheumatism • Jun 8, 2010

Authors:

Alexander So

Marc De Meulemeester

A. Pikhlak

Abstract

OBJECTIVE: To assess the efficacy and tolerability of canakinumab, a fully human anti-interleukin-1β monoclonal antibody, for the treatment of acute gouty arthritis. METHODS: In this 8-week, single-blind, double-dummy, dose-ranging study, patients with acute gouty arthritis whose disease was refract...

Subject

Canakinumab

Medicine

Triamcinolone acetonide

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!